These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31820209)

  • 1. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.
    Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
    Int J Clin Oncol; 2020 Apr; 25(4):713-719. PubMed ID: 31820209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
    Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
    Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
    Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
    Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Baumann BC; Baumann JC; Christodouleas JP; Soffen E
    Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer.
    Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
    Int J Clin Oncol; 2016 Aug; 21(4):783-790. PubMed ID: 26843024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
    Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
    Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
    BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable 10-year outcomes of image-guided intensity-modulated radiotherapy combined with long-term androgen deprivation for Japanese patients with nonmetastatic prostate cancer.
    Tomita N; Soga N; Ogura Y; Furusawa J; Tanaka H; Koide Y; Tachibana H; Kodira T
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):18-25. PubMed ID: 30411504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy for prostate cancer.
    Serizawa I; Kozuka T; Soyano T; Sasamura K; Kamima T; Kunogi H; Numao N; Yamamoto S; Yonese J; Yoshioka Y
    J Radiat Res; 2024 Sep; 65(5):693-700. PubMed ID: 39154370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experience.
    Detti B; Baki M; Becherini C; Saieva C; Scartoni D; Giacomelli I; Trombetta L; Muntoni C; Olmetto E; Francolini G; Turkaj A; Topulli J; Ciabatti C; Carta G; Poggesi L; Delli Paoli C; Terziani F; Grassi R; Livi L
    Radiol Med; 2019 May; 124(5):422-431. PubMed ID: 30607866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
    Tandberg DJ; Oyekunle T; Lee WR; Wu Y; Salama JK; Koontz BF
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):396-405. PubMed ID: 29559284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
    Amit U; Lawrence YR; Weiss I; Symon Z
    Radiat Oncol; 2019 Jun; 14(1):99. PubMed ID: 31182119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
    Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
    Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.
    Vuky J; Pham HT; Warren S; Douglass E; Badiozamani K; Madsen B; Hsi A; Song G
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e609-15. PubMed ID: 22208976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.